{"id":72505,"date":"2026-08-08T00:49:31","date_gmt":"2026-08-07T22:49:31","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/08\/08\/il-1-driven-systemic-inflammation-in-tumour-progression-and-metastatic-spread-jacqueline-alford\/"},"modified":"2026-08-08T00:49:31","modified_gmt":"2026-08-07T22:49:31","slug":"il-1-driven-systemic-inflammation-in-tumour-progression-and-metastatic-spread-jacqueline-alford","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/08\/08\/il-1-driven-systemic-inflammation-in-tumour-progression-and-metastatic-spread-jacqueline-alford\/","title":{"rendered":"IL-1-driven systemic inflammation in tumour progression and metastatic spread. Jacqueline Alford"},"content":{"rendered":"<div>\n<p><b>Semin Immunol<\/b>. 2026 Aug 7;83:102052. doi: 10.1016\/j.smim.2026.102052. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Inflammation is a fundamental immune response that protects against injury and infection; however, when unresolved, it can contribute to disease pathogenesis. Chronic inflammation is a hallmark of cancer that promotes tumour initiation and metastatic spread. Notably, this relationship is bidirectional: while chronic inflammation can promote tumour initiation, tumours themselves actively drive systemic inflammation. Two related members of the interleukin-1 (IL-1) family, IL-1\u03b1 and IL-1\u03b2, are pleiotropic cytokines that link local tumour activity to systemic immune dysregulation and have emerged as principal drivers of this process. Tumour-derived IL-1\u03b2 reshapes haematopoiesis in the bone marrow, promoting myeloid-skewed output and the expansion and polarisation of monocytes and neutrophils. These tumour-educated myeloid cells actively contribute to disease progression and metastatic spread through a range of mechanisms including suppression of anti-tumour immunity. In this review, we synthesise the current understanding of how tumours induce IL-1 production and how IL-1-driven systemic inflammation remodels the tumour macro-environment. We highlight emerging evidence that myeloid cell reprogramming occurs in a layered process, proposing a model of hierarchical myeloid education across the bone marrow and peripheral tissues and outline the therapeutic potential of targeting IL-1 signalling to disrupt tumour-promoting inflammation.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42566816\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=9009458&amp;ff=20260807184931&amp;v=2.20.1\">42566816<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1016\/j.smim.2026.102052\">10.1016\/j.smim.2026.102052<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Semin Immunol. 2026 Aug 7;83:102052. doi: 10.1016\/j.smim.2026.102052. Online ahead of print. ABSTRACT Inflammation is a fundamental immune response that protects against injury and infection; however, when unresolved, it can contribute to disease pathogenesis. Chronic inflammation is a hallmark of cancer that promotes tumour initiation and metastatic spread. Notably, this relationship is bidirectional: while chronic inflammation &#8230; <a title=\"IL-1-driven systemic inflammation in tumour progression and metastatic spread. Jacqueline Alford\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/08\/08\/il-1-driven-systemic-inflammation-in-tumour-progression-and-metastatic-spread-jacqueline-alford\/\" aria-label=\"Read more about IL-1-driven systemic inflammation in tumour progression and metastatic spread. Jacqueline Alford\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42,110],"tags":[],"class_list":["post-72505","post","type-post","status-publish","format-standard","hentry","category-publicaciones","category-seminars-in-immunology"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/72505","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=72505"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/72505\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=72505"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=72505"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=72505"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}